Q1 2026 · 13F-HR
Velan Capital Investment Management LPholdings as filed
Filed 2026-05-15 · accession 0001848809-26-000002
$159.6M
Reported value
49
Positions
2026-03-31
Period end
The Brief · Velan Capital Investment Management LP · Q1 2026
AI · grounded in 13F
Velan Capital Investment Management LP closed its position in CIDARA THERAPEUTICS INC, reducing exposure by $23.9M. The fund established new positions in AVR for $3.8M and XNCR for $3.0M. Additionally, the manager accumulated shares in IMMX, TENX, and STRO.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $32.5M | 20.3% | 100,781 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $14.8M | 9.25% | 2,834,652 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $12.8M | 7.99% | 512,160 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $10.3M | 6.43% | 446,255 | Common | SHARED |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $10.0M | 6.28% | 492,893 | Common | SHARED |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $9.3M | 5.84% | 583,333 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $8.6M | 5.37% | 77,000 | Common | SOLE |
| 427746102 | HRTX | HERON THERAPEUTICS INC | $7.0M | 4.39% | 8,753,290 | Common | SOLE |
| 45258H106 | IMMX | IMMIX BIOPHARMA INC | $6.7M | 4.22% | 740,000 | Common | SOLE |
| 29664W105 | ESPR | ESPERION THERAPEUTICS INC NE | $4.7M | 2.95% | 1,720,000 | Common | SOLE |
| 27966L306 | EDSA | EDESA BIOTECH INC | $4.3M | 2.71% | 827,500 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $3.9M | 2.43% | 700,000 | Common | SOLE |
| 45779A846 | NSPR | INSPIREMD INC | $3.4M | 2.14% | 2,099,652 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $3.0M | 1.89% | 250,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $2.8M | 1.73% | 185,122 | Common | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $2.5M | 1.60% | 352,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC. | $2.5M | 1.59% | 540,000 | Common | SOLE |
| 92511W207 | VRCA | VERRICA PHARMACEUTICALS INC | $2.5M | 1.56% | 471,559 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $2.3M | 1.46% | 2,668,395 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $2.3M | 1.43% | 750,000 | Common | SOLE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $2.0M | 1.28% | 102,000 | Common | SOLE |
| 74319B502 | PROF | PROFOUND MED CORP | $1.9M | 1.16% | 285,710 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.8M | 1.12% | 91,123 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $1.1M | 0.66% | 294,643 | Common | SOLE |
| 48669G303 | KZIA | KAZIA THERAPEUTICS LTD | $1.0M | 0.63% | 135,315 | Common | SOLE |
| M7071P109 | NSRX | NASUS PHARMA LTD | $797,846 | 0.50% | 359,390 | Common | SOLE |
| 74907L409 | QNRX | QUOIN PHARMACEUTICALS LTD | $560,003 | 0.35% | 84,849 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $407,550 | 0.26% | 6,500 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $389,980 | 0.24% | 3,700 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $355,200 | 0.22% | 160,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $297,990 | 0.19% | 11,000 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $262,000 | 0.16% | 100,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $248,000 | 0.16% | 16,000 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $244,140 | 0.15% | 26,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $233,600 | 0.15% | 10,000 | Common | SOLE |
| 74019P207 | DTIL | PRECISION BIOSCIENCES INC | $220,000 | 0.14% | 40,000 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $218,700 | 0.14% | 10,000 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $212,800 | 0.13% | 20,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $161,000 | 0.10% | 25,000 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $156,000 | 0.10% | 80,000 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $153,000 | 0.10% | 20,000 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $148,500 | 0.09% | 33,000 | Common | SOLE |
| 98422T209 | XLO | XILIO THERAPEUTICS INC | $120,137 | 0.08% | 14,285 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $103,860 | 0.07% | 18,000 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $90,520 | 0.06% | 73,000 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $86,700 | 0.05% | 30,000 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $83,550 | 0.05% | 15,000 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $72,900 | 0.05% | 45,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $22,995 | 0.01% | 70,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.